GlycanAge
- Company typePrivate
- Founded2016
- HeadquartersNewcastle Upon Tyne, United Kingdom
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
GlycanAge firmographics
Firmographics- Name
- GlycanAge
- Legal name
- GlycanAge Ltd
- Website
- https://glycanage.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
GlycanAge industry classification
Industry- Product category
- Biological Age Diagnostics
- NAICS
- Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
Keywords
Where GlycanAge is headquartered
LocationHeadquarters
- HQ city
- Newcastle Upon Tyne
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
GlycanAge business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Direct-to-Consumer Biological Age Testing: GlycanAge sells biological age test kits directly to consumers through its e-commerce website. Customers purchase test kits (annual subscription, bi-annual subscription, one-off purchase, or two-test bundle) and receive at-home testing kits with personalized reports and specialist consultations included.
- Healthcare Provider / Hospital Integration: GlycanAge deploys its biomarker technology into hospital and clinical settings for routine cardiometabolic risk screening. The company validates diagnostic indications and develops lab-developed tests for hospital settings, generating revenue through clinical partnerships and testing services.
- Research Collaborations: GlycanAge provides its technology and research capabilities to academic and clinical research institutions studying aging, inflammation, and longevity. Collaborations with institutions like Buck Institute for Research on Aging and Mayo Clinic support scientific advancement while generating revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Annual subscription plan with 10% savings |
| Subscription | Multi-year contract | Bi-annual subscription with 15% savings - ideal for tracking active lifestyle changes |
| One time/ perpetual license | Pay-as-you-go | One-off standalone test |
| Unit Pricing | Pay-as-you-go | Two-test bundle with 10% savings |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels7 records
GlycanAge product offering
Product offeringCore offering
GlycanAge provides a glycan-based biological age testing service that measures patterns of glycans attached to immunoglobulin G antibodies through an at-home finger-prick blood test. Results are delivered as personalized biological age reports combined with 1:1 longevity specialist consultations, with three primary service lines: personal-use test kits for consumers, clinical integration for healthcare providers and longevity clinics, and research services for academic institutions.
Product overview
GlycanAge offers a glycan-based biological age testing platform with three primary service lines: personal use (at-home testing with finger-prick blood sample), healthcare provider integration (for clinicians and longevity practices), and research services. The core product is the GlycanAge test, which measures glycans on immunoglobulin G antibodies to estimate biological age and track immune system aging. Results are delivered as personalized reports with 1:1 specialist consultations. The company offers multiple subscription tiers (annual, bi-annual, one-off, bundle) priced at approximately £342-379, and operates across approximately 2,000 clinics in 64 markets.
Differentiator
Problem solved
Functional benefit
Products and services
- GlycanAge Biological Age Test (Personal Use) At-home biological age testing service for individuals, comprising a finger-prick blood collection kit (four drops of blood on a collection card, returned in a prepaid envelope), a personalized biological age and inflammatory profile report delivered in 3-4 weeks, and a 1:1 longevity specialist consultation to interpret results and recommend lifestyle changes. Designed for health-conscious individuals interested in longevity, biohacking, and personalized preventive healthcare.
- GlycanAge for Healthcare Providers
Quantifiable outcome
- Therapeutic plasma exchange produces −0.4 years per month reduction in glycan age, the largest among tested interventions (hormone replacement therapy and caloric restriction)
- +2 more outcomes
Companies that use GlycanAge
Customer profileNamed customers11 records
Segments3 records
Ideal customer profiles3 records
GlycanAge technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
GlycanAge partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered strategic and core.
- Mayo ClinicstrategicCo-organizer of the ISABS conference with GlycanAge's 'Inflammaging in Clinical Practice' satellite event, positioning the company within prestigious medical conference series.
- ISABS (International Society for Applied Biological Sciences)strategicProfessional society co-organizing the conference series where GlycanAge hosts its inflammaging satellite event, marking 25 years of inflammaging research.
- Circulate HealthcoreCo-authored landmark study validating glycans as aging biomarkers with investigators from GlycanAge and Buck Institute for Research on Aging, advancing evidence-based TPE protocols through longevity clinics.
- St. Catherine Specialty HospitalcoreFirst hospital deployment of GlycanAge's biomarker technology in Zagreb, integrating glycan biomarkers into routine cardiometabolic risk screening - serving as the flagship hospital integration reference.
- King Abdulaziz City for Science and TechnologystrategicSaudi Arabia's national research center partnering with GlycanAge to establish a Middle East laboratory for expanding diagnostic capabilities in the region.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
GlycanAge competitors and assessment
Company assessmentEmerging players
- Fountain Life: Fountain Life operates premium longevity clinics offering advanced diagnostics (full-body MRI, blood biomarkers, AI-driven health assessments) and would be a relevant peer given GlycanAge's push to integrate glycan biomarkers into longevity clinic and hospital workflows as an embedded diagnostic layer.
- Viome Life Sciences: Viome provides at-home microbiome and gene expression testing combined with personalized nutrition recommendations, overlapping with GlycanAge's D2C longevity testing and personalization model but using a different biological measurement modality (gut microbiome and mRNA rather than glycan biomarkers).
Direct peers
- TruDiagnostic: TruDiagnostic offers epigenetic age testing and multi-omic biomarker analysis to both consumers and clinicians, with a strong focus on clinical research partnerships and longevity clinics — closely paralleling GlycanAge's consumer-plus-healthcare-provider model and biological age biomarker positioning.
- InsideTracker: InsideTracker provides at-home blood-based biomarker testing with personalized longevity and performance recommendations, offering a comparable D2C subscription model and serving overlapping health-optimization consumers who want measurable biological age and healthspan insights.
- ZOE: ZOE combines at-home blood, microbiome, and continuous glucose testing with personalized nutrition guidance for health-conscious consumers. It targets the same longevity/wellness segment as GlycanAge and competes on integrated biomarker testing plus lifestyle recommendations and 1:1 specialist interpretation.
- Tally Health: Tally Health is a D2C biological age testing company offering at-home epigenetic age tests and longevity supplements, directly competing with GlycanAge in the consumer longevity testing category with overlapping target customers (biohackers, health-conscious consumers) and similar subscription pricing models.
- Elysium Health: Elysium Health developed the Index at-home biological age test measuring cellular health via DNA methylation, and supplements (Basis). It competes directly with GlycanAge in the consumer biological age testing space and shares a similar science-led brand positioning backed by academic researchers.
- Function Health: Function Health offers comprehensive at-home blood-based health testing (100+ biomarkers) with clinician review, targeting the same health-conscious consumer and longevity-conscious segment as GlycanAge, with a similar premium subscription model and at-home finger-prick collection approach.
Broad incumbents
- Human Longevity Inc. Human Longevity Inc. provides comprehensive whole-genome sequencing, advanced imaging, and full-body diagnostics through premium executive health programs, competing with GlycanAge in the premium longevity diagnostics segment via a much broader (and higher-priced) multi-omics offering aimed at ultra-high-net-worth longevity clients.
- Genentech Glycobiology Programs: Genentech (Roche) operates large-scale glycobiology and biopharma research programs and represents a broad incumbent in the glycobiology space whose commercial drug pipelines (e.g., glyco-engineered antibodies) demonstrate the broader pharmaceutical potential of IgG glycan science that GlycanAge's biomarker platform is built upon.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
GlycanAge social profiles
Digital presenceGlycanAge compliance and trust
Trust signalCompliance1 record
GlycanAge financial estimates
Financial estimateRevenue estimate
Valuation estimate
GlycanAge leadership team
Management profileNumber of profiles
Profiles3 records
GlycanAge funding detail
Funding detailFunding overview
Funding rounds6 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GlycanAge M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GlycanAge
What does GlycanAge do?
GlycanAge provides a glycan-based biological age testing service that measures patterns of glycans attached to immunoglobulin G antibodies through an at-home finger-prick blood test. Results are delivered as personalized biological age reports combined with 1:1 longevity specialist consultations, with three primary service lines: personal-use test kits for consumers, clinical integration for healthcare providers and longevity clinics, and research services for academic institutions.
Is GlycanAge a public or private company?
GlycanAge is a private company. It is classified as venture growth investor backed and is currently operating.
When was GlycanAge founded?
GlycanAge was founded in 2016. It employs 11 to 50 people.
Where is GlycanAge based?
GlycanAge is headquartered in Newcastle Upon Tyne, United Kingdom, in the Europe region.
How does GlycanAge make money?
Three revenue lines are on record. Direct-to-Consumer Biological Age Testing is the primary driver. The others are healthcare Provider / Hospital Integration and research Collaborations.
Who are GlycanAge's main competitors?
Emerging players on record are Fountain Life and Viome Life Sciences. Direct peers are TruDiagnostic, InsideTracker, ZOE, Tally Health, Elysium Health and Function Health. Broad incumbents are Human Longevity Inc. and Genentech Glycobiology Programs.
Does GlycanAge have an API?
No public API is recorded for GlycanAge.
What industry is GlycanAge in?
GlycanAge's product category is Biological Age Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 62151 and its SIC code is 2835.